ABSTRACT
We present three cases of eosinophilic granulomatosis with polyangiitis (EGPA) where patients experienced relapse of eosinophilic sinusitis without peripheral eosinophilia while on remission maintenance therapy with mepolizumab (MPZ), an anti-interleukin (IL)-5 monoclonal antibody. Despite the initial control of symptoms with high-dose prednisolone (PSL) and MPZ, patients experienced a relapse of nasal obstruction and eosinophilic infiltration in nasal mucosal biopsies. Notably, relapses occurred despite normal peripheral eosinophil counts, indicating the localized nature of eosinophilic inflammation. While IL-5 inhibitors effectively reduce peripheral blood eosinophils, eosinophilic sinusitis may persist due to local factors such as IL-4-mediated inflammation. IL-4 has been implicated in promoting eosinophil migration into nasal tissues, suggesting that IL-5 inhibitors alone may not sufficiently suppress eosinophilic infiltration in such cases. These findings highlight the importance of considering the possibility of eosinophilic sinusitis relapse in EGPA patients treated with IL-5 inhibitors and reduced glucocorticoid doses. Further research is warranted to elucidate the mechanisms underlying local eosinophilic inflammation and optimize treatment strategies for EGPA patients.
Subject(s)
Antibodies, Monoclonal, Humanized , Eosinophilia , Granulomatosis with Polyangiitis , Recurrence , Sinusitis , Humans , Antibodies, Monoclonal, Humanized/therapeutic use , Sinusitis/drug therapy , Sinusitis/complications , Male , Middle Aged , Female , Granulomatosis with Polyangiitis/drug therapy , Granulomatosis with Polyangiitis/complications , Eosinophilia/drug therapy , Interleukin-5/antagonists & inhibitors , Eosinophils , Adult , AgedABSTRACT
OBJECTIVES: To efficiently detect somatic UBA1 variants and establish a clinical scoring system predicting patients with pathogenic variants in VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome. METHODS: Eighty-nine Japanese patients with clinically suspected VEXAS syndrome were recruited [81 males and 8 females; median onset age (IQR) 69.3 years (62.1-77.6)]. Peptide nucleic acid-clamping PCR (PNA-PCR), regular PCR targeting exon 3 clustering UBA1 variants, and subsequent Sanger sequencing were conducted for variant screening. Partitioning digital PCR (pdPCR) or targeted amplicon deep sequencing (TAS) was also performed to evaluate the variant allele frequency (VAF). We developed our clinical scoring system to predict UBA1 variant-positive and negative patients and assessed the diagnostic value of our system using receiver operating characteristic (ROC) curve analysis. RESULTS: Forty patients with reported pathogenic UBA1 variants (40/89, 44.9%) were identified, including a case having a variant with VAF of 1.7%, using a highly sensitive method. Our clinical scoring system considering >50 years of age, cutaneous lesions, lung involvement, chondritis, and macrocytic anaemia efficiently predicted patients with UBA1 variants (the area under the curve for the scoring total was 0.908). CONCLUSIONS: Genetic screening with the combination of regular PCR and PNA-PCR detected somatic UBA1 variants with high sensitivity and specificity. Our scoring system could efficiently predict patients with UBA1 variants.
ABSTRACT
ABSTRACT: A 57-year-old woman was referred for progressive dyspnea. CT showed a tracheal mass, suspicious of tracheal neoplasm. The lesion was partially resected, and nonspecific granulation tissue was observed on histology. Her symptoms and CT findings worsened. FDG PET/CT showed increased FDG accumulation in the nasal septum and left eustachian tube in addition to the tracheobronchial lesions. Although the patient was ANCA (antineutrophil cytoplasmic antibodies) negative, a differential diagnosis of granulomatosis with polyangiitis was established and confirmed pathologically. FDG PET/CT was useful for diagnosis of ANCA-negative granulomatosis with polyangiitis, in which tracheobronchial and cartilage lesions were prominent.
Subject(s)
Antibodies, Antineutrophil Cytoplasmic , Granulomatosis with Polyangiitis , Cartilage , Female , Fluorodeoxyglucose F18 , Granulomatosis with Polyangiitis/diagnostic imaging , Humans , Middle Aged , Positron Emission Tomography Computed TomographyABSTRACT
AIM: Subjective well-being (SWB) is a psychological construct that is synonymous with happiness. Many variables including age, sex, income, employment, and marital status are related to SWB. Health is also an important determinant of SWB that can be adversely affected in patients with chronic conditions such as rheumatoid arthritis (RA). In this study, we evaluate the SWB of RA patients and compare it with that of healthy controls. METHODS: We obtained the original dataset from the "Quality of Life Survey, 2013", which was conducted by the Economic and Social Research Institute, Cabinet Office, Government of Japan. In this survey, SWB was determined by asking participants to rate their happiness between 0 (very unhappy) and 10 (very happy). The survey also included a 56-point questionnaire regarding well-being-related variables. This questionnaire was administered to RA patients recruited from Kobe University Hospital, and clinical and treatment data were simultaneously collected. RESULTS: Multivariate analysis revealed that RA patients with high or moderate disease activity had SWB scores that were similar to those of controls. However, the SWB scores of RA patients in remission or with low disease activity were higher than those of controls (P = .013). SWB was associated with household income, self-assessment of living costs, self-assessment of health, depression/ anxiety, and social connection. CONCLUSIONS: For RA patients, achieving the therapeutic target can result in better SWB than that of healthy controls. Financial status, self-assessment of health, psychological stress, and social network are also important determinants for the SWB of RA patients.
Subject(s)
Adaptation, Psychological , Arthritis, Rheumatoid/psychology , Health Status , Marital Status , Quality of Life , Social Welfare/psychology , Cross-Sectional Studies , Female , Follow-Up Studies , Humans , Japan , Male , Middle Aged , Retrospective Studies , Social Behavior , Socioeconomic Factors , Surveys and QuestionnairesABSTRACT
Purpose To evaluate the incidence of fragility fractures associated with high-dose glucocorticoid therapy in patients with systemic rheumatic disease. METHODS: A retrospective study of patients who were treated with high-dose prednisolone (> 0.8 mg/kg) for systemic rheumatic disease at Kobe University Hospital from April 1988 to March 2012. The primary outcome was a major osteoporotic fracture (defined as a clinical vertebral, hip, forearm, or proximal humerus fracture) after high-dose glucocorticoid therapy. For postmenopausal women and men over 40 of age, the patient's fracture risk at the beginning of high-dose glucocorticoid therapy was assessed by the World Health Organization's Fracture Risk Assessment Tool (FRAX®). Results Of 229 patients (median age: 49 years), 57 suffered a fragility fracture during the observation period (median observation period: 1558 days). Of 84 premenopausal patients, 5 suffered a fracture. In contrast, of 86 postmenopausal female, 36 suffered a fracture. Fragility fractures were far more frequent than predicted by the FRAX® score. Patients with FRAX® scores over 8.3% had a particularly high risk of fracture. Conclusions Fragility fractures associated with high-dose glucocorticoid therapy are common among postmenopausal women. Extreme care should be taken especially for postmenopausal women when high-dose glucocorticoid therapy is required.
ABSTRACT
A 78-year-old female with massive pericardial effusion fulfilled diagnostic criteria for immunoglobulin G4 (IgG4)-related disease. Although her adenosine deaminase (ADA) level in the pericardial effusion was high, all the tests for tuberculosis infection were negative. Immunostaining of the pericardium biopsy specimen revealed remarkably increased IgG4-positive cells. This is the first report describing IgG4-related pericarditis with elevated ADA level. We also demonstrate the elevated interleukin-10 (IL-10) level in pericardial fluid and IL-10-producing T-cells in the pericardium.
Subject(s)
Adenosine Deaminase/analysis , Hypergammaglobulinemia , Immunoglobulin G/immunology , Interleukin-10/analysis , Pericardial Fluid/immunology , Pericarditis, Tuberculous/diagnosis , Pericarditis , Aged , Diagnosis, Differential , Female , Humans , Hypergammaglobulinemia/complications , Hypergammaglobulinemia/diagnosis , Hypergammaglobulinemia/immunology , Male , Patient Acuity , Pericardial Effusion/diagnosis , Pericardial Effusion/etiology , Pericardial Effusion/immunology , Pericarditis/diagnosis , Pericarditis/etiology , Pericarditis/immunology , Pericardium/immunologyABSTRACT
In rheumatoid arthritis (RA), synovial fibroblasts (RA-SFs) accumulate in affected joints, where they play roles in inflammation and joint destruction. RA-SFs exhibit tumor-like proliferation and are resistant to apoptosis. Although RA-SF activation is well described, negative regulators of RA-SF activation are unknown. We previously reported that histone deacetylase (HDAC) inhibitors facilitate apoptosis in RA-SFs. Here we found that RA-SFs treated with the HDAC inhibitor Trichostatin A (TSA) exhibited an upregulation of the immediate early response gene X-1 (IEX-1). IEX-1 has roles in apoptosis sensitivity, cell-cycle progression, and proliferation, and is reported to be involved in immune responses, inflammation, and tumorigenesis, and to have anti-arthritic properties. To investigate IEX-1's role in RA-SFs, we used in vitro-cultured synovial fibroblasts from RA and osteoarthritis (OA) patients. We confirmed that TSA upregulated the IEX-1 protein and mRNA expressions in RA-SFs by western blotting and quantitative RT-PCR. Inhibiting HDAC1, 2, and 3 (but not 6 or 8) also upregulated IEX-1. The IEX-1 mRNA levels were higher in RA-SFs than in OA-SFs, and were further upregulated in RA-SFs by the pro-inflammatory cytokines TNFα and IL-1ß. The staining of surgical specimens showed that IEX-1 was present in the pannus from affected RA joints. Si-RNA-mediated IEX-1 knockdown upregulated the lipopolysaccharide (LPS)-induced expression of TNFα and various chemokine mRNAs, indicating that IEX-1 downregulates TNFα and chemokines. Furthermore, apoptosis analysis showed that IEX-1 knockdown protected RA-SFs from apoptosis induced by TSA or by an anti-Fas mAb, indicating that IEX-1 is pro-apoptotic in RA-SFs. Collectively, our results showed that IEX-1 is induced by TNFα and IL-1ß in RA-SFs, in which it suppresses TNFα and chemokine production and induces apoptosis; thus, IEX-1 negatively regulates RA-SF activation. Further investigation of IEX1's functions in RA-SFs may lead to new therapeutic approaches for RA.
Subject(s)
Apoptosis Regulatory Proteins/genetics , Apoptosis Regulatory Proteins/metabolism , Arthritis, Rheumatoid/pathology , Fibroblasts/cytology , Membrane Proteins/genetics , Membrane Proteins/metabolism , Synovial Membrane/cytology , Apoptosis , Arthritis, Rheumatoid/genetics , Arthritis, Rheumatoid/metabolism , Cells, Cultured , Chemokines/genetics , Chemokines/metabolism , Fibroblasts/drug effects , Fibroblasts/metabolism , Humans , Hydroxamic Acids/pharmacology , Osteoarthritis/genetics , Osteoarthritis/metabolism , Osteoarthritis/pathology , Synovial Membrane/drug effects , Synovial Membrane/metabolism , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism , Up-RegulationABSTRACT
Osteoporosis is a common and under-diagnosed disease characterized by the systemic impairment and structural deterioration of bone tissue, leading to bone fragility and an increased risk of fractures of the hip, spine, and wrist. Recent progress in osteoporosis revealed new information on its pathogenesis, the relative risks of fragility fractures, and new treatment measures. In the wake of progress in osteoporosis research, the Japanese Society for Bone and Mineral Research (JSBMR) and Japan Osteoporosis Society Joint Review Committee revised the diagnostic criteria for primary osteoporosis, aimed at obtaining international consensus on the new findings, in 2012. The JSBMR also published guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis in that year. Then, the JSBMR revised the guidelines on the management and treatment of glucocorticoid-induced osteoporosis in 2014. This article focuses on the diagnosis and pharmacological treatment of osteoporosis, with an overview of the Japanese guidelines.
Subject(s)
Osteoporosis/diagnosis , Osteoporosis/drug therapy , Absorptiometry, Photon , Biomarkers , Bone Density Conservation Agents/administration & dosage , Cholecalciferol/administration & dosage , Diphosphonates/administration & dosage , Fractures, Spontaneous/etiology , Humans , Osteoporosis/etiology , Practice Guidelines as Topic , Reference Standards , Risk , Selective Estrogen Receptor Modulators/administration & dosageABSTRACT
OBJECTIVE: Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells that have the ability to suppress T cell responses. The aim of this study was to evaluate the effects of the JAK inhibitor tofacitinib on MDSCs in a mouse model of rheumatoid arthritis. METHODS: Arthritis was induced in SKG mice by zymosan A (ZyA) injection. MDSCs isolated from the bone marrow (BM) of donor SKG mice with arthritis were adoptively transferred to recipient mice with arthritis. In a separate experiment, tofacitinib was administered to arthritic SKG mice subcutaneously via osmotic pump, in some cases followed by injection of an anti-Gr-1 monoclonal antibody (mAb). BM cells from untreated mice were cultured for 5 days with granulocyte-macrophage colony-stimulating factor, with or without tofacitinib, and then analyzed by flow cytometry. RESULTS: The numbers of MDSCs and polymorphonuclear MDSCs (PMN-MDSCs) were significantly increased in the spleens of SKG mice following ZyA injection. Adoptive transfer of MDSCs to recipient arthritic mice reduced the severity of arthritis compared to that in untreated control mice. Treatment with tofacitinib also ameliorated the progression of arthritis in SKG mice and induced significantly higher numbers of MDSCs and PMN-MDSCs in the BM of these animals. Furthermore, administration of an anti-Gr-1 mAb reduced the antiarthritic effect of tofacitinib in SKG mice. In vitro, tofacitinib facilitated the differentiation of BM cells to MDSCs, and inhibited their differentiation to dendritic cells. CONCLUSION: Tofacitinib facilitates the expansion of MDSCs and ameliorates arthritis in SKG mice.
Subject(s)
Arthritis, Experimental/drug therapy , Cell Differentiation/drug effects , Piperidines/therapeutic use , Protein Kinase Inhibitors/therapeutic use , Pyrimidines/therapeutic use , Pyrroles/therapeutic use , Animals , Arthritis, Experimental/immunology , CD4-Positive T-Lymphocytes/drug effects , CD4-Positive T-Lymphocytes/immunology , Dendritic Cells/immunology , Female , Mice , Piperidines/pharmacology , Protein Kinase Inhibitors/pharmacology , Pyrimidines/pharmacology , Pyrroles/pharmacologyABSTRACT
BACKGROUND: TAFRO syndrome is a unique clinicopathologic variant of multicentric Castleman's disease that has recently been identified in Japan. It is characterized by a constellation of symptoms: Thrombocytopenia, Anasarca, reticulin Fibrosis of the bone marrow, Renal dysfunction and Organomegaly (TAFRO). Previous reports have shown that affected patients usually respond to immunosuppressive therapy, but the disease sometimes has a fatal course. TAFRO syndrome occurs in the middle-aged and elderly and there are no prior reports of the disease in adolescents. Here we report the first adolescent case, successfully treated with anti-IL-6 receptor antibody (tocilizumab, TCZ) and monitored with serial cytokine profiles. CASE PRESENTATION: A 15-year-old Japanese boy was referred to us with fever of unknown origin. Whole body computed tomography demonstrated systemic lymphadenopathy, organomegaly and anasarca. Laboratory tests showed elevated C-reactive protein and hypoproteinemia. Bone marrow biopsy revealed a hyperplastic marrow with megakaryocytic hyperplasia and mild reticulin fibrosis. Despite methylprednisolone pulse therapy, the disease progressed markedly to respiratory distress, acute renal failure, anemia and thrombocytopenia. Serum and plasma levels of cytokines, including IL-6, vascular endothelial growth factor, neopterin and soluble tumor necrosis factor receptors I and II, were markedly elevated. Repeated weekly TCZ administration dramatically improved the patient's symptoms and laboratory tests showed decreasing cytokine levels. CONCLUSION: To our knowledge, this is the first report of TAFRO syndrome in a young patient, suggesting that this disease can occur even in adolescence. The patient was successfully treated with TCZ. During our patient's clinical course, monitoring cytokine profiles was useful to assess the disease activity of TAFRO syndrome.
Subject(s)
Acute Kidney Injury/etiology , Bone Marrow/pathology , Edema/diagnosis , Primary Myelofibrosis/diagnosis , Thrombocytopenia/diagnosis , Acute Kidney Injury/drug therapy , Adolescent , Anemia/drug therapy , Anemia/etiology , Antibodies, Monoclonal, Humanized/therapeutic use , C-Reactive Protein/analysis , Cytokines/blood , Edema/drug therapy , Humans , Hypoproteinemia/diagnosis , Japan , Lymphatic Diseases/diagnosis , Lymphatic Diseases/drug therapy , Male , Primary Myelofibrosis/drug therapy , Respiratory Insufficiency/drug therapy , Respiratory Insufficiency/etiology , Reticulin , Syndrome , Thrombocytopenia/drug therapySubject(s)
Gas Chromatography-Mass Spectrometry , Lupus Erythematosus, Systemic/blood , Metabolomics/methods , Biomarkers/blood , Case-Control Studies , Discriminant Analysis , Female , Glucocorticoids/therapeutic use , Humans , Immunosuppressive Agents/therapeutic use , Least-Squares Analysis , Lupus Erythematosus, Systemic/drug therapy , Prednisolone/therapeutic use , Principal Component AnalysisABSTRACT
OBJECTIVES: Recent studies have shown that mycophenolate mofetil (MMF) is similar to intravenous cyclophosphamide (IVC) for the treatment of lupus nephritis (LN), but that treatment response may vary according to location and race/ethnicity. Moreover, no studies have been conducted to compare the efficacy of MMF with that of IVC for a Japanese population. We therefore conducted a retrospective study to clarify the efficacy and safety of MMF compared with that of IVC for induction therapy for active LN, classes III and IV, in a Japanese population of 21 patients, 11 of whom received MMF and 10 IVC. METHODS: The primary endpoint was expressed as the percentage of responders, who in turn were defined as the patients who met complete or partial response criteria according to the European consensus statement. The secondary endpoints comprised the renal activity component and serological activity. RESULTS: The primary endpoint was achieved in nine (81.8 %) patients receiving MMF and in four (40.0 %) receiving IVC, with no significant difference between the two groups (p = 0.081), while there was also no significant difference between them in terms of secondary endpoints. However, the MMF group suffered significantly fewer hematologic toxic effects than the IVC group. CONCLUSIONS: MMF may be used as an alternative to IVC for inducing renal remission of LN in Japanese patients.
Subject(s)
Cyclophosphamide/therapeutic use , Immunosuppressive Agents/therapeutic use , Lupus Nephritis/drug therapy , Mycophenolic Acid/analogs & derivatives , Adult , Asian People/ethnology , Cyclophosphamide/administration & dosage , Cyclophosphamide/adverse effects , Drug Therapy, Combination , Endpoint Determination , Female , Glucocorticoids/therapeutic use , Hematologic Diseases/chemically induced , Humans , Immunosuppressive Agents/adverse effects , Induction Chemotherapy , Injections, Intravenous , Japan/epidemiology , Lupus Nephritis/ethnology , Male , Mycophenolic Acid/adverse effects , Mycophenolic Acid/therapeutic use , Remission Induction , Retrospective StudiesABSTRACT
OBJECTIVE: To establish proper management of Pneumocystis jiroveci pneumonia (PCP) in rheumatoid arthritis (RA) patients treated with infliximab. PCP has been observed in 0.4% of patients with RA treated with infliximab in Japan. METHODS: Data from patients with RA (n = 21) who were diagnosed with PCP during infliximab treatment and from 102 patients with RA who did not develop PCP during infliximab therapy were collected from 14 rheumatology referral centers in Japan. A retrospective review of these patients and a case-control study to compare patients with and without PCP were performed. RESULTS: The median length of time from the first infliximab infusion to the development of PCP was 8.5 weeks. At the onset of PCP, the median dosages of prednisolone and methotrexate were 7.5 mg/day and 8 mg/week, respectively. Pneumocystis jiroveci was microscopically identified in only 2 patients, although the polymerase chain reaction test for the organism was positive in 20 patients. The patients with PCP had significantly lower serum albumin levels (P < 0.001) and lower serum IgG levels (P < 0.001) than the patients without PCP. Computed tomography of the chest in all patients with PCP revealed ground-glass opacity either with sharp demarcation by interlobular septa or without interlobular septal boundaries. Sixteen of the 21 patients with PCP developed acute respiratory failure, but all survived. CONCLUSION: PCP is a serious complication that may occur early in the course of infliximab therapy in patients with RA. For the proper clinical management of this infectious disease, physicians need to be aware of the possibility of PCP developing during infliximab therapy.
Subject(s)
Antibodies, Monoclonal/adverse effects , Antirheumatic Agents/adverse effects , Arthritis, Rheumatoid/drug therapy , Pneumocystis carinii , Pneumonia, Pneumocystis/etiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Aged , Anti-Infective Agents/therapeutic use , Female , Humans , Infliximab , Male , Middle Aged , Pneumocystis carinii/isolation & purification , Pneumonia, Pneumocystis/diagnosis , Pneumonia, Pneumocystis/drug therapy , Retrospective Studies , Risk Factors , Trimethoprim, Sulfamethoxazole Drug Combination/therapeutic use , Tumor Necrosis Factor-alpha/immunologyABSTRACT
SS-A/Ro52 (Ro52) protein is one of the targets of autoantibodies in Sjogren's syndrome and systemic lupus erythematosus. Ro52 structurally belongs to the RING-B-box/coiled-coil family, which appears to carry out diverse functions, but the physiological function of Ro52 remains largely unknown. Here, the authors demonstrate that hydrogen peroxide but not other oxidative stressors induced translocation of Ro52 protein from the cytoplasm to the nucleus and this phenomenon was attenuated by inhibition of MAP kinases, ERK in particular. These findings raise the possibility that SS-A/Ro52 may function as a hydrogen peroxide-selective, oxidative stress-sensitive signaling molecule that is activated via the MAP kinase pathway.